Industry Roundup: Cardinal Buys Harvard Drug, Similac Lawsuit, State AGs Question Supplement Oversight
This article was originally published in The Tan Sheet
Executive Summary
Cardinal acquires Harvard Drug; Similac ‘organic’ claims deceptive – complaint; N.Y., Ind. criticize supplement regulatory flexibility; Amway headquarters manufacturing site opens; and more news in brief.
You may also be interested in...
Health And Wellness Industry Regulatory Roundup
Warning letter a year after recall; spiked supplement total climbs; FTC-USDA "organic" roundtable; and FTC ISO ICA for Herbalife.
PharmaTech Adds Supplements To Recall Nearly A Month After Drugs
In addition to Major and Rugby supplement brands marketed by Cardinal Health subsidiary Harvard Health Group, PharmaTech's recall includes products it makes for the BProtected, Renew HC and Cytodetox brands.
Harvard Drug Continues Expansion With Watson’s Rugby OTC Business
Watson Pharmaceuticals sells OTC business Rugby Laboratories to Harvard Drug Group, which operates Major Pharmaceuticals manufacturing. Watson divests a business that accounted for a small part of the private label OTC market, but keeps its pending ANDAs for guaifenesin expectorants and its smoking-cessation generics.